Codexis, Inc. (NASDAQ:CDXS) Stock Holdings Lifted by BNP Paribas Arbitrage SA

BNP Paribas Arbitrage SA lifted its position in Codexis, Inc. (NASDAQ:CDXSGet Rating) by 594.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 189,115 shares of the biotechnology company’s stock after acquiring an additional 161,873 shares during the period. BNP Paribas Arbitrage SA’s holdings in Codexis were worth $5,914,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in CDXS. FMR LLC increased its position in shares of Codexis by 25.6% in the first quarter. FMR LLC now owns 917,537 shares of the biotechnology company’s stock worth $18,837,000 after acquiring an additional 187,000 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Codexis in the third quarter worth approximately $601,000. Advisor Group Holdings Inc. increased its position in shares of Codexis by 70.4% in the third quarter. Advisor Group Holdings Inc. now owns 3,814 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 1,576 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Codexis by 3.9% in the third quarter. Principal Financial Group Inc. now owns 25,255 shares of the biotechnology company’s stock worth $588,000 after acquiring an additional 955 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Codexis by 153.3% in the third quarter. Barclays PLC now owns 55,782 shares of the biotechnology company’s stock worth $1,297,000 after acquiring an additional 33,761 shares in the last quarter.

In other news, Director Dennis P. Wolf sold 4,000 shares of the business’s stock in a transaction on Wednesday, March 23rd. The shares were sold at an average price of $20.49, for a total value of $81,960.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John J. Nicols sold 38,500 shares of the business’s stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $10.31, for a total transaction of $396,935.00. Following the completion of the sale, the chief executive officer now owns 1,022,679 shares of the company’s stock, valued at $10,543,820.49. The disclosure for this sale can be found here. Insiders sold 81,000 shares of company stock valued at $1,207,700 over the last 90 days. 7.50% of the stock is owned by corporate insiders.

CDXS has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Codexis from a “buy” rating to a “hold” rating in a research report on Tuesday. StockNews.com initiated coverage on shares of Codexis in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Cowen initiated coverage on shares of Codexis in a research report on Wednesday, March 2nd. They set a “buy” rating and a $39.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Codexis in a research report on Friday, February 25th. Finally, TheStreet downgraded shares of Codexis from a “c-” rating to a “d” rating in a research report on Thursday, February 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Codexis presently has a consensus rating of “Buy” and a consensus target price of $30.83.

NASDAQ CDXS opened at $10.97 on Friday. The company has a 50 day moving average price of $16.93 and a two-hundred day moving average price of $24.10. Codexis, Inc. has a 12-month low of $9.47 and a 12-month high of $42.01.

Codexis (NASDAQ:CDXSGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The firm had revenue of $35.34 million during the quarter, compared to analysts’ expectations of $28.58 million. Codexis had a negative net margin of 16.85% and a negative return on equity of 12.56%. The company’s revenue was up 96.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.14) earnings per share. As a group, analysts anticipate that Codexis, Inc. will post -0.44 EPS for the current fiscal year.

Codexis Profile (Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Read More

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXSGet Rating).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.